Risedronic acid

Generic Name: Risedronic acid

Brand Names: Actonel, Atelvia

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₁NO_₇P_₂

CAS Number: 105462-24-6

Unique Ingredient Identifier: KM2Z91756Z

Background: Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.

Associated Conditions: Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease

Associated Therapies: -

Clinical Trials

Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo risedronate oral tablet
Drug: risedronate

First Posted Date: 2009-03-10

Last Posted Date: 2018-05-01

Lead Sponsor: UConn Health

Target Recruit Count: 50

Registration Number: NCT00859027

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

Completed

Conditions: Osteoporosis

Interventions: Drug: risedronate

First Posted Date: 2009-02-05

Last Posted Date: 2013-06-05

Lead Sponsor: Warner Chilcott

Target Recruit Count: 29

Registration Number: NCT00837746

Locations: 🇺🇸
Ronald D Emkey, MD, Wyomissing, Pennsylvania, United States
🇺🇸
Maria Greenwald, MD, Palm Desert, California, United States
🇺🇸
Paul Miller, MD, Lakewood, Colorado, United States

and more 5 locations

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

Phase 4

Terminated

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Risedronate
Drug: Raloxifene
Other: Placebo

First Posted Date: 2008-11-13

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT00790101

Locations: 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

Phase 4

Completed

Conditions: Bone Loss

Interventions: Drug: Risedronate
Drug: Placebo

First Posted Date: 2008-10-15

Last Posted Date: 2014-09-19

Lead Sponsor: Danderyd Hospital

Target Recruit Count: 78

Registration Number: NCT00772395

Locations: 🇸🇪
Orthopaedic department, Danderyd Hospital, Stockholm, Sweden

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: Risedronate

First Posted Date: 2008-09-19

Last Posted Date: 2011-10-12

Lead Sponsor: Warner Chilcott

Target Recruit Count: 76

Registration Number: NCT00755872

Locations: 🇺🇸
Research Site, Austin, Texas, United States

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

Phase 1

Completed

Conditions: Postmenopausal
Non-lactating
Surgically Sterile

Interventions: Drug: risedronate

First Posted Date: 2008-07-16

Last Posted Date: 2011-10-12

Lead Sponsor: Warner Chilcott

Target Recruit Count: 94

Registration Number: NCT00717145

Locations: 🇺🇸
Research Site, Austin, Texas, United States
🇺🇸
Research site, Miramar, Florida, United States

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Osteoporosis

Interventions: Drug: Risedronate

First Posted Date: 2008-06-18

Last Posted Date: 2013-04-17

Lead Sponsor: Warner Chilcott

Target Recruit Count: 96

Registration Number: NCT00699777

Locations: 🇺🇸
Research Site, Gainesville, Florida, United States
🇺🇸
Research Facility, Dallas, Texas, United States

Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects

Phase 2

Completed

Conditions: Post-menopausal Osteoporosis

Interventions: Drug: Ibandronate
Drug: Risedronate
Drug: Alendronate

First Posted Date: 2008-04-25

Last Posted Date: 2018-03-06

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 410

Registration Number: NCT00666627

Locations: 🇬🇧
Academic Unit of Bone Metabolism (Sheffield), Sheffield, South Yorkshire, United Kingdom

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis, Postmenopausal

First Posted Date: 2008-03-10

Last Posted Date: 2008-03-11

Lead Sponsor: Sanofi

Target Recruit Count: 464

Registration Number: NCT00632216

Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

Phase 3

Completed

Conditions: Other Osteoporosis

Interventions: Drug: Placebo tablet
Drug: Risedronate

First Posted Date: 2008-02-21

Last Posted Date: 2011-10-28

Lead Sponsor: Warner Chilcott

Target Recruit Count: 285

Registration Number: NCT00619957

Locations: 🇭🇺
Research Facility, Budapest, Hungary
🇬🇧
Research Site, Sheffield, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy